Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Jivi Market Growth Potential: How Will Market Size Shift Through 2030?
Historically, growth was driven by the frequent occurrence of bleeding episodes in hemophilia A, the recognized limitations of standard factor VIII therapies, the early acceptance of recombinant factors, an increased emphasis on preventing joint damage, and the expansion of hemophilia treatment centers.
Growth during the projected timeframe is expected to stem from the increased utilization of long-acting clotting factors, greater availability of home infusion services, broader development of pediatric hemophilia treatment, favorable reimbursement frameworks, and advancements in recombinant therapies. Key developments anticipated in the forecast period encompass an increasing embrace of extended half-life Factor VIII, a move towards preventative hemophilia management, a preference for less frequent injections, the growth of in-home hemophilia care, and enhanced patient compliance with treatment.
Get A Free Sample Report With In-Depth Market Insights:
Jivi Market Growth Catalysts And Demand Drivers
The increasing incidence of hemophilia is projected to drive the expansion of the jivi market. Hemophilia results from genetic defects in X-linked genes that affect the production of clotting factors, specifically Factor VIII (hemophilia A) or IX (hemophilia B), leading to insufficient or faulty factors that hinder effective blood clotting. This rise in hemophilia cases is attributed to enhanced diagnostic methods, greater public awareness, and more widespread reporting globally. Jivi assists hemophilia patients by providing a long-acting recombinant Factor VIII replacement, which helps in blood clotting to manage or prevent bleeding events. Its prolonged half-life also means less frequent dosing, improving patient ease and compliance. For example, in April 2025, Hemophilia News Today, a US-based medical news platform, reported an estimated 836,000 people globally living with hemophilia, with approximately 284,000 experiencing the severe form. Consequently, the growing occurrence of hemophilia is a significant factor boosting the jivi market.
Jivi Market Segmentation And Category Overview
The jivi market covered in this report is segmented –
1) By Formulation: Lyophilized Powder For Reconstitution, Ready-to-use Formulations
2) By Route of Administration: Intravenous, Subcutaneous
3) By Indication: Treatment Of Hemophilia A, Prophylaxis, On-demand Treatment For Bleeding Episodes
4) By Distribution Channel: Direct Sales, Wholesalers And Distributors, Retail Pharmacies
5) By End Use: Hospitals, Hemophilia Treatment Centres, Specialty Clinics, Home Healthcare Settings
Jivi Market Competitive Analysis Of Leading Industry Participants
Major companies operating in the jivi market are Bayer AG
View The Full Jivi Market Report:
Jivi Market Regional Split: Which Areas Are Fueling Growth?
North America was the largest region in the jivi market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the jivi market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
